Specialized Proresolving Lipid Mediators: A Potential Therapeutic Target for Atherosclerosis

Area of Science:

• Lipid mediator research
• Cardiovascular pharmacology
• Inflammation resolution biology

Background:

• Cardiovascular disease (CVD) presents a significant global health challenge, necessitating novel therapeutic strategies.
• Specialized proresolving lipid mediators (SPMs), derived from omega-3 and omega-6 fatty acids, are recognized for their anti-inflammatory properties.
• SPMs encompass four families: Lipoxins, Resolvins, Protectins, and Maresins, and are increasingly studied for their therapeutic potential.

Purpose of the Study:

• To review the therapeutic impact of SPMs in cardiovascular disease (CVD).
• To explore the molecular pathways involved in SPM-mediated resolution of inflammation in CVD.
• To assess the current evidence from preclinical and clinical studies regarding SPMs for CVD treatment.

Main Methods:

• Systematic review of preclinical animal models investigating SPM efficacy in atherosclerosis, intimal hyperplasia, and reperfusion injury.
• Analysis of in vitro studies examining the mechanisms of action of SPMs.
• Integration of findings from available clinical studies on SPM application in CVD.

Main Results:

• Preclinical studies demonstrate that SPMs can mitigate the progression of atherosclerosis, intimal hyperplasia, and reperfusion injury.
• SPMs exert their effects through diverse molecular mechanisms that promote the resolution of inflammation.
• In vitro studies provide promising results regarding the efficacy and safety of SPMs.

Conclusions:

• SPMs exhibit significant therapeutic potential for cardiovascular disease (CVD) based on preclinical evidence.
• Further large-scale clinical trials are essential to validate the efficacy of SPMs in human CVD patients.
• SPMs may represent a novel and effective therapeutic alternative for managing CVD in the near future.